Clozapine-Induced Tardive Dyskinesia and Hypothyroidism

Journal of Neuropsychiatry (Impact Factor: 2.82). 02/2006; 18(2):245-6. DOI: 10.1176/appi.neuropsych.18.2.245
Source: PubMed
Download full-text


Available from: Harpreet Duggal, May 16, 2015
    • "Pillai et al.[35] described occurrence of diabetic ketoacidosis in a 45-year-old schizophrenic patient on clozapine, which ultimately led to death in the case. Mendhekar and Duggal[36] described development of tardive dyskinesia (TD) in a patient diagnosed with schizophrenia and hypothyroidism and receiving clozapine 150 mg/day along with thyroid supplement. The TD did not change in frequency and intensity, with change in dose of clozapine to either 125 mg/day or 200 mg/day. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clozapine has been used in the treatment of schizophrenia for about two decades and extensive data have been accumulated with regard to its use in various parts of the world. However, in contrast to Western countries, there are few studies which have evaluated the usefulness of clozapine in Indian patients. This article attempts to review the available data on clozapine originating from India. This review reflects the fact that there are few studies from the Indian subcontinent and most of these are case reports. In view of the same, there is a need for further research to evaluate the effectiveness of clozapine in India.
    Indian Journal of Psychiatry 04/2010; 52(2):168-73. DOI:10.4103/0019-5545.64592
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The most volatile organic compounds, remaining at the flow stream from the two cyclons placed at the exit of a coal fluidised bed combustor (200 g/h) and compiled at the US-EPA list as the Polycyclic Aromatic Hydrocarbons (PAH) priority pollutants are studied in this paper. This air flow has been forced to go throughout different trapping systems and the PAH deposited on filters and adsorbents, after being solubilised in dimethylformamide (DMF), have been analysed by synchronous fluorescence spectroscopy (FS). Results are analysed and commented.
  • Source

    The Journal of Neuropsychiatry and Clinical Neurosciences 02/2009; 21(1):104-5. DOI:10.1176/appi.neuropsych.21.1.104 · 2.82 Impact Factor
Show more